Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02412462
Recruitment Status : Completed
First Posted : April 9, 2015
Last Update Posted : June 28, 2017
Sponsor:
Information provided by (Responsible Party):
Alethia Biotherapeutics

Brief Summary:
This is a Phase 1 clinical study to investigate the safety, pharmacokinetics and pharmacodynamics of AB-16B5 in patients with an advanced solid malignancy. AB-16B5 is a humanized monoclonal antibody that inhibits the activity of the secreted form of clusterin (sCLU), a potent inducer of the epithelial-to-mesenchymal transition (EMT). Eligible subjects will have a disease that has been refractory to prior therapy and is unlikely to benefit from known therapies.

Condition or disease Intervention/treatment Phase
Solid Tumor Metastatic Cancer Drug: AB-16B5 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AB-16B5 in Subjects With an Advanced Solid Malignancy
Study Start Date : April 2015
Actual Primary Completion Date : January 2017
Actual Study Completion Date : January 2017

Arm Intervention/treatment
Experimental: AB-16B5
Single-arm study of AB-16B5 given as a 60-minute intravenous weekly infusion. One cycle of treatment will consist of 21 days. The dose levels that will be assessed are 1.5, 3.0, 6.0, 9.0 and 12 mg/kg.
Drug: AB-16B5



Primary Outcome Measures :
  1. Number of participants with an adverse event as a measure of safety and tolerability [ Time Frame: Up to treatment discontinuation + 30 days with an estimated treatment duration of 6 to 24 weeks ]

Secondary Outcome Measures :
  1. Determination of plasma concentrations of AB-16B5 [ Time Frame: Several time-points during Cycle 1 and Cycle 2 for a total of 6 weeks ]
  2. Objective tumor responses in subjects with measurable disease according to RECIST [ Time Frame: Up to treatment discontinuation + 30 days with an estimated treatment duration of 6 to 24 weeks ]
  3. Monitoring of epithelial-to-mesenchymal (EMT) and stem cells biomarkers in peripheral blood circulating tumor cells and paired tumor biopsies [ Time Frame: Up to treatment discontinuation + 30 days with an estimated treatment duration of 6 to 24 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects with a histologically or cytologically confirmed advanced solid malignancy that has been refractory to prior therapy and is unlikely to benefit from known therapies.
  • Subjects may have measurable or non-measurable but evaluable disease.
  • Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 and an estimated life expectancy of at least 12 weeks.
  • Subjects must be ≥ 18 years old.
  • Male, or female subjects who are post-menopausal (amenorrheic for at least 12 months), or surgically or biologically sterile. Females of childbearing potential with a negative serum pregnancy test prior to entering the study and using adequate forms of contraception for the duration of the study, including 30 days after the last treatment. Males should avoid fathering children during the course of the study, and adequate methods of contraception should be used by both male and female subjects. Subjects and their partners with reproductive potential must use an effective contraceptive method while the subject is on the study treatment and for 30 days after the last treatment.
  • Subjects must have adequate organ and immune function as indicated by the following laboratory values:

    • ANC ≥ 1.5 X 109/L
    • Platelets > 100 X 109/L
    • Hemoglobin ≥ 90 g/L
    • Serum creatinine ≤ 132 µmol/L
    • Total Bilirubin ≤ 1.5 X ULN
    • AST (SGOT) and ALT (SGPT) ≤ 3 X ULN* or;

      • 5 X ULN* (if hepatic metastases present)

        • ULN: Institution's upper limit of normal
  • Subjects enrolled in the standard dose escalation portion of the study must have a tumor lesion amenable for biopsy with no contraindications for biopsy.
  • Subjects must understand and be able and willing and likely to fully comply with the study procedures, including scheduled follow-up, and restrictions.
  • Subjects must have given written personally signed and dated informed consent to participate in the study, in accordance with the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines, before completing any study related procedures.

Exclusion Criteria:

  • Subjects with medical, social, or psychosocial factors that, in the opinion of the Investigator, could impact safety or compliance with study procedures.
  • Prior cancer therapy including surgery, radiotherapy, chemotherapy, hormonal and biological therapies within 3 weeks prior to study treatment.
  • Uncontrolled brain metastases.
  • Uncontrolled infection.
  • Clinically significant ECG abnormalities.
  • Known hypersensitivity of Grade > 2 to previous monoclonal antibody therapy.
  • History of alcohol or other substance abuse within the last year.
  • Use of another investigational agent in a clinical trial within the last 4 weeks prior to study treatment.
  • Female subjects who are pregnant or lactating, including females with a positive pregnancy test at screening must be excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02412462


Locations
Layout table for location information
Canada, Quebec
Jewish General Hospital
Montreal, Quebec, Canada, H3T 1E2
Sponsors and Collaborators
Alethia Biotherapeutics

Layout table for additonal information
Responsible Party: Alethia Biotherapeutics
ClinicalTrials.gov Identifier: NCT02412462     History of Changes
Other Study ID Numbers: AB-16B5-101
First Posted: April 9, 2015    Key Record Dates
Last Update Posted: June 28, 2017
Last Verified: July 2016
Keywords provided by Alethia Biotherapeutics:
Phase I
Clusterin
Epithelial-to-Mesenchymal Transition (EMT)
Circulating Tumor Cells (CTC)
EMT and Stem Cell Biomarkers
Pharmacokinetics
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Neoplasms
Neoplastic Processes
Pathologic Processes